Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Nonacog Beta Pegol · Rebinyn

Recombinant protein · Protein replacement · developed by Novo Nordisk

Approved FDA, May 2017
NVO Developer
1 Registered trials

What is Nonacog Beta Pegol?

Nonacog beta pegol is a recombinant coagulation factor IX that has been glycoPEGylated. It is studied in haemophilia B, a bleeding disorder caused by deficiency of factor IX.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Rebinyn
Drug type
Recombinant protein
Mechanism
Protein replacement
Pathways
blood coagulation
Therapy area
Hematology
Developer
Novo Nordisk Inc. (NVO)
FDA status
Approved as Rebinyn (May 31, 2017), BLA125611
UNII
27Y83O992Q

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03690336 N/A Haemophilia B Enrolling by invitation NVO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Haemophilia B

More from Novo Nordisk

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the NVO page.

Follow NVO, the company behind Nonacog Beta Pegol

See NVO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NVO catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.